Literature DB >> 6290540

Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.

M O Thorner, R L Perryman, M J Cronin, A D Rogol, M Draznin, A Johanson, W Vale, E Horvath, K Kovacs.   

Abstract

A 21-yr-old woman with Turner's syndrome presented with signs and symptoms of acromegaly. The serum growth hormone (GH) (95+/-9.4 ng/ml; mean+/-SEM) and somatomedin C (11 U/ml) levels were elevated, and an increase in GH levels after glucose instead of normal suppression, increase after thyrotropin-releasing hormone (TRH) administration instead of no change, and decrease after dopamine administration instead of stimulation were observed. The pituitary fossa volume was greater than normal (1,440 mm(3)) and the presence of a pituitary tumor was assumed. After tissue removal at transsphenoidal surgery, histological study revealed somatotroph hyperplasia rather than a discrete adenoma. Postoperatively, she remained clinically acromegalic and continued to show increased GH and somatomedin levels. A search was made for ectopic source of a growth hormone-releasing factor (GRF). Computer tomographic scan revealed a 5-cm Diam tumor in the tail of the pancreas. Following removal of this tumor, serum GH fell from 70 to 3 ng/ml over 2 h, and remained low for the subsequent 5 mo. Serum somatomedin C levels fell from 7.2 to normal by 6 wk postoperatively. There were no longer paradoxical GH responses to glucose, TRH, and dopamine. Both the medium that held the tumor cells at surgery and extracts of the tumor contained a peptide with GRF activity. The GRF contained in the tumor extract coeluted on Sephadex G-50 chromatography with rat hypothalamic GH-releasing activity. Stimulation of GH from rat somatotrophs in vitro was achieved at the nanomolar range, using the tumor extract. The patient's course demonstrates the importance of careful interpretation of pituitary histology. Elevated serum GH and somatomedin C levels in a patient with an enlarged sella turcica and the characteristic responses seen in acromegaly to TRH, dopamine, and glucose do not occur exclusively in patients with discrete pituitary tumors and acromegaly. This condition can also occur with somatotroph hyperplasia and then revert to normal after removal of the GRF source. Thus, in patients with acromegaly a consideration of ectopic GRF secretion should be made, and therefore, careful pituitary histology is mandatory. Consideration for chest and abdominal computer tomographic scans before pituitary surgery, in spite of their low yield, may be justified.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6290540      PMCID: PMC370309          DOI: 10.1172/jci110708

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  38 in total

1.  A patient suffering from Turner's syndrome and acromegaly.

Authors:  C H WILLEMSE
Journal:  Acta Endocrinol (Copenh)       Date:  1962-02

2.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

Review 3.  Pituitary adenomas.

Authors:  K Kovacs; E Horvath; C Ezrin
Journal:  Pathol Annu       Date:  1977

4.  Identification and purification of factor B-GHRH from hypothalami which releases growth hormone.

Authors:  K N Johansson; B L Currie; K Folkers; C Y Bowers
Journal:  Biochem Biophys Res Commun       Date:  1974-09-23       Impact factor: 3.575

5.  Selective growth hormone and cyclic AMP stimulating activity is present in human pancreatic islet cell tumor.

Authors:  M J Cronin; A D Rogol; L G Dabney; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1982-08       Impact factor: 5.958

6.  Pituitary function after removal of pituitary microadenomas in Cushing's disease.

Authors:  A M Schnall; J S Brodkey; B Kaufman; O H Pearson
Journal:  J Clin Endocrinol Metab       Date:  1978-08       Impact factor: 5.958

7.  Neuron-specific enolase is produced by neuroendocrine tumours.

Authors:  F J Tapia; J M Polak; A J Barbosa; S R Bloom; P J Marangos; C Dermody; A G Pearse
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

8.  Acromegaly associated with a bronchial carcinoid tumor: evidence for ectopic production of growth hormone-releasing activity.

Authors:  M Saeed uz Zafar; R C Mellinger; G Fine; M Szabo; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

9.  Plasma growth hormone responses to intrapituitary injections of growth hormone releasing factor (GRF) in the rat.

Authors:  L A Frohman; J W Maran; A P Dhariwal
Journal:  Endocrinology       Date:  1971-06       Impact factor: 4.736

10.  Rapid regression of pituitary prolactinomas during bromocriptine treatment.

Authors:  M O Thorner; W H Martin; A D Rogol; J L Morris; R L Perryman; B P Conway; S S Howards; M G Wolfman; R M MacLeod
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  70 in total

Review 1.  Aspects of anterior pituitary growth, with special reference to corticotrophs.

Authors:  A M McNicol; E Carbajo-Perez
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

2.  Acromegaly: disease or syndrome? Not only a semantic question.

Authors:  Giovanni Faglia
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

3.  Evidence for growth hormone (GH) autoregulation in pituitary somatotrophs in GH antagonist-transgenic mice and GH receptor-deficient mice.

Authors:  S L Asa; K T Coschigano; L Bellush; J J Kopchick; S Ezzat
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Metabolic clearance and plasma disappearance rates of human pancreatic tumor growth hormone releasing factor in man.

Authors:  L A Frohman; J L Thominet; C B Webb; M L Vance; H Uderman; J Rivier; W Vale; M O Thorner
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

Review 5.  [Space occupying processes of the sellar region with emphasis on tumor-like lesions].

Authors:  W Saeger
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

6.  Human pancreatic growth hormone-releasing factor (hpGRF): dose-response of GRF- and GH-levels.

Authors:  M Losa; G K Stalla; O A Müller; K von Werder
Journal:  Klin Wochenschr       Date:  1983-12-15

7.  Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis.

Authors:  K Kovacs; E Horvath; M O Thorner; A D Rogol
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

8.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

9.  Recent developments in the treatment of acromegaly.

Authors:  D K Lüdecke
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

10.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.